At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PLSE Pulse Biosciences
Trading 04-16 10:10:22 EDT
20.10
+0.46
+2.32%
High20.11Low19.80Vol24.13K
Open19.91D1 Closing19.65Amplitude1.55%
Mkt Cap1.36BTradable Cap350.51MTotal Shares67.77M
T/O482.11KT/O Rate0.14%Tradable Shares17.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pulse Biosciences Updates 2026 Cardiac Ablation Strategy
TIPRANKS  ·  15 minutes ago
Pulse Biosciences Updates 2026 Cardiac Ablation Strategy
Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story?
Simply Wall St.  ·  04-12
Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story?
BRIEF-Pulse Biosciences Strengthens Executive Leadership Team
Reuters  ·  04-09
BRIEF-Pulse Biosciences Strengthens Executive Leadership Team
Pulse Biosciences names Liane Teplitsky chief operating officer
Reuters  ·  04-09
Pulse Biosciences names Liane Teplitsky chief operating officer
Affluent Medical names Anne Lange to board, replaces Soad El Gazaoui
Reuters  ·  04-09
Affluent Medical names Anne Lange to board, replaces Soad El Gazaoui
Pulse Biosciences Launches Pivotal NANOPULSE-AF Clinical Study
TIPRANKS  ·  04-07
Pulse Biosciences Launches Pivotal NANOPULSE-AF Clinical Study
Pulse Biosciences enrolls first patients in NANOPULSE-AF pivotal trial for AF ablation system
Reuters  ·  04-07
Pulse Biosciences enrolls first patients in NANOPULSE-AF pivotal trial for AF ablation system
Pulse Biosciences Enrolls First Patients in Nanopulse-Af Ide Pivotal Clinical Study Evaluating Npulse™ Cardiac Catheter System for Atrial Fibrillation
THOMSON REUTERS  ·  04-07
Pulse Biosciences Enrolls First Patients in Nanopulse-Af Ide Pivotal Clinical Study Evaluating Npulse™ Cardiac Catheter System for Atrial Fibrillation
Is It Too Late To Consider Pulse Biosciences (PLSE) After Recent Share Price Surge?
Simply Wall St.  ·  04-03
Is It Too Late To Consider Pulse Biosciences (PLSE) After Recent Share Price Surge?
Pulse Biosciences to present at Needham Virtual Healthcare Conference
Reuters  ·  04-03
Pulse Biosciences to present at Needham Virtual Healthcare Conference
Pulse Biosciences Grants RSUs to Chief Technology Officer
TIPRANKS  ·  03-28
Pulse Biosciences Grants RSUs to Chief Technology Officer
Pulse Biosciences awards CTO Darrin R. Uecker 100,000 restricted stock units; grant vests in full on third anniversary
Reuters  ·  03-28
Pulse Biosciences awards CTO Darrin R. Uecker 100,000 restricted stock units; grant vests in full on third anniversary
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot
Simply Wall St.  ·  03-23
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot
BRIEF-Pulse Biosciences Announces Strategic Alignment To Accelerate Cardiac Catheter Program Following Exceptional Long-Term Afib Clinical Data
Reuters  ·  03-17
BRIEF-Pulse Biosciences Announces Strategic Alignment To Accelerate Cardiac Catheter Program Following Exceptional Long-Term Afib Clinical Data
Pulse Biosciences prioritizes R&D and clinical investment for its nPulse cardiac catheter pivotal IDE studies in the US and Europe
Reuters  ·  03-17
Pulse Biosciences prioritizes R&D and clinical investment for its nPulse cardiac catheter pivotal IDE studies in the US and Europe
Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma
Reuters  ·  03-12
Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors With Npulse™ Technology
THOMSON REUTERS  ·  03-12
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors With Npulse™ Technology
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn
TIPRANKS  ·  03-10
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results
TIPRANKS  ·  03-09
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results
Pulse Biosciences Announces Clinical Data From Npulse™ Vybrance™ System First-in-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
THOMSON REUTERS  ·  03-09
Pulse Biosciences Announces Clinical Data From Npulse™ Vybrance™ System First-in-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Introduction

Company Name.
Pulse Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.
Issue price:
--